C-145-04

Cervical Carcinoma

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145-04) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic cervical carcinoma.

NOW RECRUITING: A Phase 2 Study to evaluate the safety, tolerability and efficacy of cell transfer therapy using autologous tumor infiltrating lymphocytes (LN-145-04) followed by IL-2 in patients with recurrent and/or metastatic cervical carcinoma.

Key eligibility criteria:
Measurable metastatic disease and ≥ 1 lesion resectable for TIL generation
• At least one prior systemic therapy
• Age ≥ 18
• ECOG PS 0-1

Endpoints: Safety and Efficacy

Physicians

To learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts, please click here:

Identifier: NCT03108495

ClinicalTrials@Lionbio.com
1-866-860-5466 (LION)

Patients

If you have been diagnosed with recurrent and/or metastatic Cervical Carcinoma, have previously undergone at least one systemic treatment, and are interested in participating in this trial, please talk to your doctor.

If you have other questions or would like more information on this trial:

CLINICALTRIALS.GOV